Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
9
×
biotech
boston blog main
9
×
boston top stories
cancer
9
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
pfizer
clinical trials
deals
merck
roche
bristol-myers squibb
glaxosmithkline
novartis
venture capital
abbvie
astrazeneca
What
bio
roundup
cancer
conference
drug
annual
ash
buy
hit
medical
moves
patients
society
abbvie’s
acquisitions
advantages
alliance
american
appetite
bar
barbecuing
barcelona
becker
biggest
billions
black
blood
borne
bread
brings
bristol
build
butter
buyout
calls
camping
cancers
cardiologist
cash
center
Language
unset
Current search:
cancer
×
" boston blog main "
×
amgen
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More